The field of cancer immunotherapy has grown rapidly with the clinical application of checkpoint inhibitors (CPIs), particularly programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) [3,4,5]. This evidence concerns the gene CTLA4 and cancer.